Literature DB >> 3257899

Augmentative effect of Nocardia rubra cell-wall skeleton (N-CWS) on lymphokine-activated killer (LAK) cell induction.

S Yokota1, T Shirasaka, H Nishikawa, S Hosoe, T Ikeda, K Komuta, I Kawase, T Masuno, T Ogura, S Kishimoto.   

Abstract

The present study elucidated that N-CWS augments the cytolytic activity against 3LL tumor cells of LAK cells from N-CWS-immunized mice administered i.p. with rIL-2. This augmentative effect of N-CWS was not seen when the LAK cells were prepared from normal mice. The cytolytic activity was predominantly expressed in the NAPC prepared from the site of injection of rIL-2, and repeated administrations of rIL-2 were required to induce and maintain this potent cytolytic activity in vivo. Serological analysis revealed that the LAK cells were positive for Thy 1.2 and asialo GM1 antigens and that they were not classical CTL or NK cells. The administration of rIL-2 statistically prolonged the MST of mice bearing LAK-sensitive 3LL cells but not the MST of mice bearing LAK-resistant EL-4 leukemia. Furthermore, combination therapy with N-CWS and rIL-2 prolonged the MST of the mice more than the therapy with rIL-2 alone. These results suggest that LAK cells potentiated with N-CWS would be useful for immunotherapy of malignant neoplasms.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3257899     DOI: 10.1007/bf00199841

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  18 in total

1.  Killing of tumor cells in vitro by macrophages from mice given injections of squalene-treated cell wall skeleton of Nocardia rubra.

Authors:  M Ito; H Iizuka; T Masuno; R Yasunami; T Ogura; Y Yamamura; I Azuma
Journal:  Cancer Res       Date:  1981-07       Impact factor: 12.701

2.  [Immunotherapy for acute myelogenous leukemia with Nocardia rubra cell-wall skeleton. A randomized controlled study].

Authors:  H Nakamura; T Masaoka; R Ohno; K Yamada; N Ogawa
Journal:  Nihon Ketsueki Gakkai Zasshi       Date:  1983-09

3.  Mechanism(s) of in vitro macrophage activation with Nocardia rubra cell wall skeleton: the effects on macrophage activating factor production by lymphocytes.

Authors:  T Masuno; S Hayashi; M Ito; T Ikeda; T Ogura; S Kishimoto; Y Yamamura
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

4.  Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.

Authors:  M Rosenstein; I Yron; Y Kaufmann; S A Rosenberg
Journal:  Cancer Res       Date:  1984-05       Impact factor: 12.701

5.  Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer.

Authors:  A A Rayner; E A Grimm; M T Lotze; E W Chu; S A Rosenberg
Journal:  Cancer       Date:  1985-03-15       Impact factor: 6.860

6.  Effect of Nocardia rubra cell wall skeleton on T-cell-mediated cytotoxicity in mice bearing syngeneic sarcoma.

Authors:  I Kawase; M Uemiya; T Yoshimoto; T Ogura; F Hirao; Y Yamamura
Journal:  Cancer Res       Date:  1981-02       Impact factor: 12.701

7.  In vivo activation of murine natural killer cell functions by human recombinant DNA interleukin 2.

Authors:  T Sayers; H Rossiter; J Chung; A Hren; D Armerding
Journal:  Immunobiology       Date:  1985-04       Impact factor: 3.144

8.  Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2.

Authors:  J A Thompson; D J Peace; J P Klarnet; D E Kern; P D Greenberg; M A Cheever
Journal:  J Immunol       Date:  1986-12-01       Impact factor: 5.422

9.  Effect of interleukin 2 on cytotoxic effectors: I. Short-term culture of the cytotoxic effectors and the in vivo anti-tumor activity of the cultured effectors isolated from tumor site.

Authors:  C C Ting; S S Yang
Journal:  Int J Cancer       Date:  1982-11-15       Impact factor: 7.396

10.  Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

Authors:  S A Rosenberg; J J Mulé; P J Spiess; C M Reichert; S L Schwarz
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

View more
  4 in total

1.  Synergistic induction of lymphokine (IL-2)-activated killer activity by IL-2 and the polysaccharide lentinan, and therapy of spontaneous pulmonary metastases.

Authors:  K Yamasaki; S Sone; T Yamashita; T Ogura
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Augmentative effect of Nocardia rubra cell-wall skeleton on the induction of human lymphokine-activated killer (LAK) cells by the production of LAK cell helper factor(s).

Authors:  T Shirasaka; I Kawase; M Okada; M Kitahara; T Ikeda; K Komuta; S Hosoe; S Yokota; T Masuno; S Kishimoto
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Enhancement of therapeutic effect of interleukin-2 on spontaneous pulmonary metastases of Lewis lung carcinoma by killer helper factor associated with increased induction of killer activity.

Authors:  K Fukuta; S Sone; M Kitahara; M Okada; T Ogura
Journal:  Jpn J Cancer Res       Date:  1989-06

4.  Characterization and purification of an immunosuppressive factor produced by a small cell lung cancer cell line.

Authors:  T Ikeda; T Masuno; T Ogura; M Watanabe; T Shirasaka; H Hara; Y Tanio; I Kawase; S Kishimoto
Journal:  Jpn J Cancer Res       Date:  1991-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.